Literature DB >> 7665228

An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines.

C Melani1, S M Pupa, A Stoppacciaro, S Ménard, M I Colnaghi, G Parmiani, M P Colombo.   

Abstract

In this study we tested whether the pattern of cytokines expressed by human carcinomas could account for a different in vivo recruitment of leukocyte subpopulations as a part of the anti-tumor immune response. Two carcinoma cell lines, SK-OV-3 ovary carcinoma and CALU-3 lung carcinoma, were analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR), immunofluorescence and ELISA for the expression and in vitro production of cytokines with chemotactic, proinflammatory and growth-stimulating activity. Although both cell lines displayed a constitutive expression of granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage-CSF (GM-CSF), M-CSF, interleukin (IL-) 1 alpha and IL-8, only CALU-3 cell line expressed IL-10, RANTES (Regulated upon Activation, Normal T Expressed and Secreted) and monocyte-activating protein (MCP)-1. MCP-1 and IL-8 were detected by immunohistochemistry on sections from tumors xenografted in nude mice. To analyze whether the tumor-released cytokines modulate leukocytes in tumor infiltration, we studied the distribution of human peripheral blood leukocytes injected in the proximity of SK-OV-3 and of CALU-3 tumor xenografts. While SK-OV-3 was unable to recruit human leukocytes and appeared to be barely infiltrated by murine CD45+ cells, CALU-3 appeared to be rapidly and heavily infiltrated by human leukocytes which induced tumor necrosis within 18-24 hr.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665228     DOI: 10.1002/ijc.2910620514

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.

Authors:  M Watanabe; K L McCormick; K Volker; J R Ortaldo; J M Wigginton; M J Brunda; R H Wiltrout; W E Fogler
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents.

Authors:  Xueping Zhang; Kendra M Haney; Amanda C Richardson; Eden Wilson; David A Gewirtz; Joy L Ware; Zendra E Zehner; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2010-06-08       Impact factor: 2.823

3.  CCL3 Promotes Proliferation of Colorectal Cancer Related with TRAF6/NF-κB Molecular Pathway.

Authors:  Xiaoqiang Ma; Jinda Su; Shaohui Zhao; Yaqin He; Shuzhen Li; Xiaoliang Yang; Sifan Zhai; Shikuo Rong; Xin Zhang; Guangxian Xu; Xiaoliang Xie
Journal:  Contrast Media Mol Imaging       Date:  2022-07-12       Impact factor: 3.009

4.  Parathyroid chief cell adenoma associated with massive chronic parathyroiditis in a woman with hyperparathyroidism.

Authors:  Kalman Kovacs; Cecil David Bell; Jonathan Juco; Fabio Rotondo; Jennifer Anderson
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

5.  Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.

Authors:  L Hefler; C Tempfer; G Heinze; K Mayerhofer; G Breitenecker; S Leodolter; A Reinthaller; C Kainz
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

6.  CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells.

Authors:  Santosh Kumar Singh; Manoj K Mishra; Isam-Eldin A Eltoum; Sejong Bae; James W Lillard; Rajesh Singh
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.996

7.  Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.

Authors:  C De Giovanni; G Nicoletti; L Landuzzi; F Romani; S Croci; A Palladini; A Murgo; A Antognoli; M L Ianzano; V Stivani; V Grosso; M Iezzi; L Stramucci; E Barbieri; R M Lemoli; P Nanni; P-L Lollini
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.